Jonathan Medved, CEO of OurCrowd, and Dr. Morris Laster, of MigVax, discuss oral Covid-19 vaccine with Jonathan Gerber
MigVax is an affiliate of the MIGAL Galilee Research Institute. Over the last four years, they had worked to develop a successful coronavirus vaccine for chickens. When Covid-19 broke out, they transitioned into developing an oral human vaccine, which has many benefits over injection-based vaccines. Venture Capital firm OurCrowd is leading a $12 million investment round in the company.